Alkermes has chosen Cephalon as the US partner for Vivitrex#174;, its sustained-release version of naltrexone that it awaiting approval by the US FDA for the treatment of alcohol dependence. The deal is notable for a number of reasons, not least the size of the guaranteed payments and the way in which responsibilities, costs and profits will be shared by the two parties.